On Friday, Shares of Cemex SAB de CV (ADR) (NYSE:CX), gained 0.63% to $8.04.
CEMEX, S.A.B. de C.V., declared that it has signed a contract for the sale of its operations in Austria and Hungary to the Rohrdorfer Group for about €160.1 million.
The Austrian operations comprise of 24 aggregate quarries (about 6.47 million metric tons of aggregates sold in 2014) and 34 ready-mix plants (about 1.60 million cubic meters of ready-mix sold in 2014). CEMEX’s operations in Austria had net sales of about U.S.$241 million in 2014.
The Hungarian operations being divested comprise of 5 aggregate quarries (about 1.36 million metric tons of aggregates sold in 2014) and 34 ready-mix plants (about 0.46 million cubic meters of ready-mix sold in 2014). CEMEX’s operations in Hungary had net sales of about U.S.$47 million in 2014.
The proceeds obtained from this transaction will be used mainly for debt reduction and for general corporate purposes.
The closing of this transaction is subject to the satisfaction of standard conditions for this type of transaction, which comprises authorization by regulators. We presently expect to finalize this transaction during the fourth quarter of 2015.
CEMEX, S.A.B. de C.V., a building materials company, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, and other construction materials in Mexico, the United States, Northern Europe, the Mediterranean, South America, the Caribbean, and Asia.
Shares of Stryker Corporation (NYSE:SYK), inclined 0.65% to $103.64, during its last trading session.
Stryker orthopaedics declared that its 510(k) submission for the Mako total knee application has received market clearance by the U.S. Food and Drug Administration.
This clearance expands Stryker`s current Mako offering of partial knee and total hip applications to provide a comprehensive solution in the robotic reconstructive service line. “The ability to comprise a Mako total knee application with our market leading Triathlon Total Knee System represents a key milestone in reconstructive surgery,” said David K. Floyd, Group President, Orthopaedics. “We are excited about the opportunity to transform orthopaedics by furthering the growth of robotic-arm assisted surgery, and by enhancing the surgeon and patient experience.”
With the clearance of the total knee application, Stryker is preparing to initiate a limited market release by year-end.
Stryker Corporation, together with its auxiliaries, operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.
Finally, bluebird bio Inc (NASDAQ:BLUE), ended its last trade with -3.10% loss, and closed at $127.82.
bluebird bio, stated business highlights and financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Financial Results and Financial Guidance
- Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2015 were $936.4 million, contrast to $492.0 million as of December 31, 2014, an enhance of $444.4 million, which was primarily driven by the June 2015 equity financing.
- Revenues: Partnership revenue was $4.9 million for the second quarter of 2015 contrast to $6.3 million for the second quarter of 2014. Partnership revenue is primarily comprised of the amortization of deferred revenue related to our partnership agreement with Celgene.
- R&D Expenses: Research and development expenses were $44.3 million for the second quarter of 2015, contrast to $13.9 million for the same period in 2014, an enhance of $30.4 million. The enhance in research and development expenses was primarily attributable to an $11.0 million enhance in stock-based compensation expense, of which $8.5 million is non-recurring, a $10.7 million enhance in one-time in-license milestones and fees, and an enhance in expenses necessary to support the advancement of our clinical and pre-clinical programs.
- G&A Expenses: General and administrative expenses were $10.7 million for the second quarter of 2015, contrast to $5.7 million for the same period in 2014, an enhance of $5.0 million. The enhance in general and administrative expenses was primarily attributable to a $3.5 million enhance in employee- and contractor-related costs to support our overall growth.
- Net Loss: Net loss was $51.8 million for the second quarter of 2015, contrast to net loss of $1.5 million for the second quarter of 2014.
- Financial guidance: bluebird bio anticipates that its cash, cash equivalents and marketable securities of $936.4 million as of June 30, 2015 will be sufficient to fund its operations through 2018, based on the company’s current business plan.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in F
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
